Texas Yale Capital Corp. Boosts Position in Kenvue Inc. $KVUE

Texas Yale Capital Corp. boosted its holdings in Kenvue Inc. (NYSE:KVUE) by 204.5% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 72,325 shares of the company’s stock after purchasing an additional 48,575 shares during the quarter. Texas Yale Capital Corp.’s holdings in Kenvue were worth $1,174,000 as of its most recent SEC filing.

Other hedge funds also recently added to or reduced their stakes in the company. Salomon & Ludwin LLC acquired a new position in shares of Kenvue in the 3rd quarter valued at $25,000. NBT Bank N A NY raised its stake in Kenvue by 180.3% during the 3rd quarter. NBT Bank N A NY now owns 1,564 shares of the company’s stock worth $25,000 after acquiring an additional 1,006 shares in the last quarter. Cornerstone Planning Group LLC lifted its position in Kenvue by 705.2% in the third quarter. Cornerstone Planning Group LLC now owns 1,554 shares of the company’s stock valued at $25,000 after acquiring an additional 1,361 shares during the last quarter. Golden State Wealth Management LLC boosted its stake in Kenvue by 150.1% in the third quarter. Golden State Wealth Management LLC now owns 1,983 shares of the company’s stock valued at $32,000 after acquiring an additional 1,190 shares in the last quarter. Finally, Trust Co. of Vermont boosted its stake in Kenvue by 50.9% in the third quarter. Trust Co. of Vermont now owns 2,385 shares of the company’s stock valued at $39,000 after acquiring an additional 804 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Kenvue

In other news, Director Jeffrey C. Smith acquired 3,200,000 shares of the company’s stock in a transaction on Friday, December 12th. The shares were bought at an average cost of $17.37 per share, with a total value of $55,584,000.00. Following the purchase, the director owned 27,307,632 shares of the company’s stock, valued at $474,333,567.84. This represents a 13.27% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.17% of the stock is currently owned by corporate insiders.

Kenvue Stock Up 0.8%

Kenvue stock opened at $18.70 on Tuesday. The stock has a 50 day moving average of $17.42 and a two-hundred day moving average of $17.68. Kenvue Inc. has a twelve month low of $14.02 and a twelve month high of $25.17. The stock has a market capitalization of $35.82 billion, a price-to-earnings ratio of 24.93 and a beta of 0.59. The company has a current ratio of 0.98, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, February 25th. Investors of record on Wednesday, February 11th will be issued a dividend of $0.2075 per share. The ex-dividend date of this dividend is Wednesday, February 11th. This represents a $0.83 annualized dividend and a dividend yield of 4.4%. Kenvue’s dividend payout ratio (DPR) is currently 110.67%.

Analyst Ratings Changes

A number of research firms have recently commented on KVUE. Evercore set a $18.00 target price on Kenvue in a research report on Tuesday, October 28th. Edward Jones downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 3rd. Barclays lifted their price target on Kenvue from $17.00 to $18.00 and gave the stock an “equal weight” rating in a research report on Monday, November 10th. Weiss Ratings reissued a “hold (c-)” rating on shares of Kenvue in a report on Friday, January 9th. Finally, Canaccord Genuity Group restated a “hold” rating and set a $15.00 target price (down from $26.00) on shares of Kenvue in a research report on Wednesday, October 29th. Four equities research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $19.46.

Kenvue Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.